Last reviewed · How we verify
DG3173
DG3173 is a small molecule that targets the [unknown molecular target] to exert its therapeutic effects.
At a glance
| Generic name | DG3173 |
|---|---|
| Sponsor | Aspireo Pharmaceuticals Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of DG3173 is not well understood, but it is believed to work by interacting with the [unknown molecular target].
Approved indications
Common side effects
Key clinical trials
- The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (PHASE2)
- Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. (PHASE2)
- Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173 (PHASE1)
- Single Ascending Dose Tolerability Study of DG3173 (PHASE1)
- Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DG3173 CI brief — competitive landscape report
- DG3173 updates RSS · CI watch RSS
- Aspireo Pharmaceuticals Limited portfolio CI